Claims for Patent: 9,655,892

Summary for Patent: 9,655,892

Title:	Certain chemical entities, compositions and methods
Abstract:	Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.
Inventor(s):	Ren; Pingda (San Diego, CA), Liu; Yi (San Diego, CA), Wilson; Troy Edward (San Marino, CA), Li; Liansheng (San Diego, CA), Chan; Katrina (Fremont, CA), Rommel; Christian (La Jolla, CA)
Assignee:	Intellikine LLC (La Jolla, CA)
Application Number:	14/938,647
Patent Claims:	1. A method of treating non-Hodgkin lymphoma for therapeutic benefit in a subject, comprising administering to the subject an effective amount of a compound of formula: ##STR00665## or a pharmaceutically acceptable salt thereof, and further comprising administering one or more second therapeutic agents or therapy selected from chemotherapeutic agents, cytotoxic agents, and radiation therapy. 2. The method of claim 1, wherein the second therapeutic agent or therapy is an anti-CD20 antibody. 3. The method of claim 1, wherein the second therapeutic agent or therapy is rituximab. 4. The method of claim 1, wherein the second therapeutic agent or therapy is a nitrogen mustard. 5. The method of claim 1, wherein the second therapeutic agent or therapy is chlorambucil. 6. The method of claim 1, wherein the second therapeutic agent or therapy is chlorambucil, chlornaphazine, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, fludarabine, or cyclophosphamide. 7. The method of claim 1, wherein the second therapeutic agent or therapy is fludarabine, cyclophosphamide, or rituximab, or a combination thereof. 8. A method of treating chronic lymphocytic leukemia for therapeutic benefit in a subject, comprising administering to the subject an effective amount of a compound of formula: ##STR00666## or a pharmaceutically acceptable salt thereof, and further comprising administering one or more second therapeutic agents or therapy selected from chemotherapeutic agents, cytotoxic agents, and radiation therapy. 9. The method of claim 8, wherein the second therapeutic agent or therapy is an anti-CD20 antibody. 10. The method of claim 8, wherein the second therapeutic agent or therapy is rituximab. 11. The method of claim 8, wherein the second therapeutic agent or therapy is a nitrogen mustard. 12. The method of claim 8, wherein the second therapeutic agent or therapy is chlorambucil. 13. The method of claim 8, wherein the second therapeutic agent or therapy is chlorambucil, chlornaphazine, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, fludarabine, or cyclophosphamide. 14. The method of claim 8, wherein the second therapeutic agent or therapy is fludarabine, cyclophosphamide, or rituximab, or a combination thereof. 15. A method of treating leukemia or lymphoma for therapeutic benefit in a subject, comprising administering to the subject an effective amount of a compound of formula: ##STR00667## or a pharmaceutically acceptable salt thereof, and further comprising administering one or more nitrogen mustards. 16. The method of claim 15, wherein the nitrogen mustard is chlorambucil, chlornaphazine, cyclophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, or uracil mustard. 17. The method of claim 1, wherein the compound is ##STR00668## 18. The method of claim 8, wherein the compound is ##STR00669## 19. The method of claim 15, wherein the compound is ##STR00670## 20. The method of claim 1, wherein the second therapeutic agent or therapy is an mTOR inhibitor. 21. The method of claim 8, wherein the second therapeutic agent or therapy is an mTOR inhibitor.

Details for Patent 9,655,892

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2028-01-04
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2028-01-04
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2028-01-04